ABLYNX TO PRESENT AT THE 32nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE AND TO PROVIDE AN UPDATE ON ITS TTP PROGRAMME GHENT, Belgium, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that it will present at the 32^nd Annual J.P. Morgan Healthcare Conference on Thursday 16 January 2014, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). Dr Edwin Moses, CEO of Ablynx, will give a corporate presentation that will include an update on the Company's anti-vWF Nanobody, caplacizumab, to treat acquired thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. Some improvement in recruitment has been seen since amending the clinical protocol in September 2013, nevertheless, Ablynx has decided to stop recruitment of the trial now to allow earlier analysis of the data for potential proof-of-concept. Phase II data are now expected during the first half of 2014 and if the results are promising, a Phase III study is anticipated to commence in 2015. The slides may be accessed via the Company's website, www.ablynx.com, under the 'News and Events>upcoming events' section. About Ablynx Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies^®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 30 programmes in the pipeline and seven Nanobodies in clinical development. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com. For more information, please contact Ablynx: Dr Edwin Moses CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: email@example.com Marieke Vermeersch Associate Director Investor Relations t: +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e: firstname.lastname@example.org Follow us on Twitter @AblynxABLX Ablynx media relations Consilium Strategic Communications: Mary-Jane Elliott, Amber Bielecka, Lindsey Neville t: +44 207 920 2345 e: email@example.com pdf version of the press release http://hugin.info/137912/R/1754015/591769.pdf HUG#1754015
ABLYNX TO PRESENT AT THE 32nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE AND TO PROVIDE AN UPDATE ON ITS TTP PROGRAMME
Press spacebar to pause and continue. Press esc to stop.